
Multiple myeloma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised lenalidomide and
pomalidomide for patients with multiple myeloma (MM).

Multiple myeloma and listing dates

Multiple myeloma (MM) is a type of blood cancer.

Listing dates are:

-   Lenalidomide - 1 November 2009
-   Pomalidomide - 1 August 2015

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Manage work items in PaNDA

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Process written authority approval requests

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
